Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-06-19
2010-06-22
Kolker, Daniel E. (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S387100
Reexamination Certificate
active
07741448
ABSTRACT:
Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.
REFERENCES:
patent: 5861155 (1999-01-01), Lin
patent: 2004/0181042 (2004-09-01), Yanagisawa et al.
patent: 2006/0105389 (2006-05-01), Kordyum et al.
patent: 1420032 (2004-05-01), None
Rudikoff S et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA, 1982; 79(6):1979-1983.
Paul WE, Ed. Fundamental Immunology, Third Edition. Raven Press, New York, 1993, pp. 292-295.
Padlan EA et al. Structure of an antibody-antigen complex: Crystal structure of the HyHEL-10 Fab-Iysozyme complex. Proc Natl Acad Sci USA, 1989; 86:5938-5942.
K. Yanagisawa et al., “GM1 ganglioside-bound amyloid β-protein (Aβ): A possible form of preamyloid in Alzheimer's disease,” Nat. Med. 1, No. 10, Oct. 1995, pp. 1062-1066.
K. Yanagisawa et al., “GM1 Ganglioside-bound amyloid β- protein in Alzheimer's disease brain,” Neurobiol. Aging, vol. 19, No. 1S, 1998, pp. S65-S67.
J. McLaurin et al., “Membrane Disruption by Alzheimer β-Amyloid Peptides Mediated through Specific Binding to Either Phospholipids or Gangliosides,” J. Biol. Chem. vol. 271, No. 43, 1996, pp. 26482-26489.
L. P. Choo-Smith et al., “The interaction between Alzheimer amyloid β(1-40) peptide and ganglioside GM1-containing membranes,” FEBS Letters, vol. 402, 1997, pp. 95-98.
J. McLaurin et al., “Characterization of the interactions of Alzheimer β-amyloid peptides with phospholipid membranes,” Eur J Biochem. 245(2), 1997, pp. 355-363.
L. P.Choo-Smith et al., “Acceleration of Amyloid Fibril Formation by Specific Binding of Aβ-(1-40) Peptide to Ganglioside-containing Membrane Vesicles,” J. Biol. Chem., vol. 272, No. 37, 1997, pp. 22987-22990.
K. Matsuzaki et al., “Interactions of Amyloid β-Peptide (1-40) with Ganglioside-Containing Membranes,” Biochemistry 38, 1999, pp. 4137-4142.
V. Koppaka et al., “Accelerated Accumulation of Amyloid β Protein on Oxidatively Damaged Lipid Membranes,” Biochemistry 39, 2000, pp. 10011-10016.
A. Kakio et al., “Cholesterol-dependent Formation of GM1 Ganglioside-bound Amyloid (β-Protein , an Endogenous Seed for Alzheimer Amyloid,” J.Biol. Chem, vol. 276, No. 27, 2001, pp. 24985-24990.
U. Igbavboa et al.. “Increasing Age Alters Transbilaver Fluidity and Cholesterol Asymmetry in Synaptic Plasma Membranes of Mice,” J. Neurochem., vol. 66, No. 4, 1996, pp. 1717-1725.
U. Igbavboa, et al., “Transbilayer Distribution of Cholesterol Is Modified in Brain Synaptic Plasma Membranes of Knockout Mice Deficient in the Low-Density Lipoprotein Receptor, Apolipoptotein E, or Both Proteins,” J. Neurochem. vol. 69, No. 4, 1997, pp. 1661-1667.
R. G. Parton, “Ultrastructural Localization of Gangliosides; GM1 is Concentrated in Caveolae,” J. Histochem. Cytochem. vol. 42, No. 2, 1994, pp. 155-166.
K. Simons et al., “Functional rafts in cell membranes,” Nature vol. 387, Jun. 1997, pp. 569-572.
S. J. Lee et al., “A detergent-insoluble membrane compartment contains Aβ in vivo,” Nat. Med. vol. 4, No. 6, Jun. 1998, pp. 730-734.
M. Morishima-Kawashima et al., “The Presence of Amyloid β-Protein in the Detergent-Insoluble Membrane Compartment of Human Neuroblastoma Cells,” Biochemistry, vol. 37, No. 44, Nov. 1998, pp. 15274-15253.
N. Sawamura et al., “Mutant Presenilin 2 Transgenic Mice,” J. Biol. Chem., vol. 275, No. 36, 2000, pp. 27901-27908.
Katsuhiko Yanagisawa et al., “Amyloid- β-protein (Aβ) associated with lipid molecules: immunoreactivity distinct from that of soluble Aβ,”FEBS Letters 420,1997, pp. 43-46.
Hideki Hayashi et al., “A Seed for Alzheimer Amyloid in the Brain,” J Neurosci., 24(20), May 2004, pp. 4894-4902.
Katsuhiko Yanagisawa, Heisei 14 Nendo Sokatsu Buntan Kenkyu Hokokusho, 2004, pp. 11-14.
Shibata Masao
Yanagisawa Katsuhiko
Ballard Kimberly A.
Edwards Angell Palmer & & Dodge LLP
Kolker Daniel E.
Medical & Biological Laboratories Co. Ltd.
The President of National Center for Geriatrics and Gerontology
LandOfFree
Antibody having inhibitory effect on amyloid fibril formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody having inhibitory effect on amyloid fibril formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody having inhibitory effect on amyloid fibril formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196125